| Patient | Winston Churchill |
|---|---|
| Date of birth | 1947-11-30 |
| Identifiers | MRN HR-ET001-SYN; SSN (made up) 000-01-8846 |
| Document date | 2026-08-19 |
| Author | Beatrice Okafor, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week stroke and blood pressure review. [S]
Mr. Churchill returns eight weeks after his stroke and three weeks after the sick visit at which amlodipine was reduced to 5 mg for orthostatic lightheadedness. The lightheadedness resolved within two days, and his home standing pressures have been 120 to 130 systolic. He has had no falls and no new neurological symptoms. He walks outdoors without a stick and his handwriting is nearly normal. He has started chairing meetings at work again, for half days. The 30-day heart monitor was returned five days ago. He is down to about four cigars a day and no longer drinks in the afternoon. His mood is better and he cries less often. [S]
| Element | Detail |
|---|---|
| Interval change | Orthostatic symptoms resolved after reducing amlodipine |
| Function | Walking outdoors without a stick; handwriting nearly normal; half days at work |
| Home blood pressure | Standing 120 to 130 systolic |
| Tobacco and alcohol | About four cigars a day; no afternoon drinking |
| Mood | Better; tearful less often |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving |
| Cardiovascular | Negative | No lightheadedness, chest pain, or palpitations |
| Neurological | Negative | No new weakness, numbness, speech change, or visual loss |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Psychiatric | Negative | Mood improving; sleeping better; no thoughts of self-harm; PHQ-9 score 6 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily for 21 days with clopidogrel | One tablet by mouth daily | Oral route | 2026-06-23 to 2026-07-14 | completed | S |
| Clopidogrel 75 mg oral tablet, one tablet by mouth daily (after a 300 mg loading dose in the hospital) | One tablet by mouth daily | Oral route | 2026-06-23 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-06-23 | active | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-06-26 to 2026-07-01 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-07-01 to 2026-07-29 | completed | S |
| Lisinopril 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-07-15 | active | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-07-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-19 | Body height | 168 | cm | S |
| 2026-08-19 | Body weight | 79 | kg | S |
| 2026-08-19 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-08-19 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-08-19 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-19 | Heart rate | 70 | /min | S |
| 2026-08-19 | Respiratory rate | 16 | /min | S |
| 2026-08-19 | Body temperature | 36.7 | Cel | S |
| 2026-08-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-19 | Cholesterol [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-08-19 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-19 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-19 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 58 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-08-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-56 U/L | Normal | S |
| 2026-08-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-08-19 | Total score [AUDIT-C] | 5 | {score} | S |
Vital signs recorded on 2026-08-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and animated |
| Orthostatic vital signs | Seated 128/76 mmHg; standing 124/74 mmHg, no symptoms |
| Heart | Regular rhythm; no murmur |
| Neurological | Faint left pronator drift only; speech normal |
| Gait | Normal pace without a stick; slight left circumduction when tired |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Mild left hemiparesis and dysarthria after a right-hemisphere lacunar infarct eight days before intake; synthetic modern episode linked to the documented 1953 stroke | active | confirmed | I69.354 | S — Synthetic modern diagnosis; the 1953 stroke remains D in the history. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis supported by the documented raised blood pressure after the 1953 stroke. |
| Nicotine dependence, cigars, six to eight a day | active | confirmed | F17.290 | S — Synthetic coded diagnosis echoing the documented lifelong cigar smoking. |
| Orthostatic hypotension after antihypertensive intensification in hot weather, resolved after reducing amlodipine | resolved | confirmed | I95.1 | S — Synthetic medication-related intercurrent problem at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure seated and standing, weight and BMI | Every visit | Completed today | Seated 128/76 mmHg, standing 124/74 mmHg; weight 79.0 kg; target met without orthostatic hypotension |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin, then every 3 to 12 months | Completed today | Eight weeks after starting atorvastatin 80 mg. LDL cholesterol 58 mg/dL, below the 70 mg/dL target |
| Laboratory | ALT | Baseline, then only with symptoms | Completed today | 28 U/L, normal |
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting an ACE inhibitor, then every 6 months | Up to date | Drawn at the sick visit two weeks after lisinopril was started: potassium 4.6, creatinine 1.12 mg/dL; next in about six months |
| Imaging | Prolonged cardiac rhythm monitoring | At least 30 days within 6 months of the stroke | Completed today | 30 days of monitoring reviewed: sinus rhythm throughout, no atrial fibrillation or flutter |
| Medication safety | Antithrombotic and statin adherence | Every visit | Completed today | Taking clopidogrel and atorvastatin; no bleeding or myalgia |
| Examination | Fall-risk assessment | Every visit | Completed today | One near-fall with orthostatic hypotension three weeks ago; none since |
| Survey | Depression screen (PHQ-9) | First post-stroke visit, then periodically while symptoms persist; at least yearly | Completed today | 6, down from 8; item 9 scored 0; no treatment needed |
| Survey | Alcohol use (AUDIT-C) | Every visit | Completed today | 5, down from 8; brief intervention repeated |
| Self-management | Tobacco use | Every visit | Completed today | About four cigars a day; goal of three agreed |
| Examination | Obstructive sleep apnea evaluation | Consider for all after stroke | Deferred | STOP-Bang 3 (age, sex, and hypertension), with no loud snoring, witnessed apneas, or sleepiness beyond his habitual afternoon nap. Sleep testing was offered and he declined it for now, a deviation from the protocol recorded here. No harm is evident; corrective action: the question will be asked again at each review and testing arranged if symptoms appear |
| Referral | Physical and occupational therapy | Through recovery | Completed today | Continuing; expected discharge next month |
| Survey | Cognitive screen (MoCA) | Again within the first year | Due | Planned at the annual wellness visit |
| Medication safety | Influenza vaccination | Yearly | Due | This season's vaccine due in the autumn |
Goal progress:
Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021); 2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke (2024); CMID: Clinical Monitoring Intelligence Database, stroke/TIA, hypertension, and depression monographs (2026)
Follow-up: Three-month stroke review in about seven weeks. Next scheduled visit 2026-10-07: three-month stroke review before returning to public speaking. [S]